OncoMatch/Clinical Trials/NCT05687747

Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma

Is NCT05687747 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI for hepatocellular carcinoma.

Phase 1RecruitingNational University Hospital, SingaporeNCT05687747Data as of May 2026

Treatment: Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI — Single centre prospective evaluation of 68Gallium(Ga68)-FAPI-46 PET/MRI in patients diagnosed with Hepatocellular Carcinoma (HCC). 68Gallium-FAPI-46 PET/MRI and standard contrasted multiphasic MRI imaging will be acquired in patients with radiological or histological diagnosis of HCC. The PET scan results will be compared to standard imaging to evaluate its role in lesion detection, characterisation and staging in patients with HCC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Prior therapy

No prior treatment (treatment-naive required)

Cannot have received: locoregional therapy

Lab requirements

Kidney function

creatinine clearance > 30ml/min based on cockcroft gault formula

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify